120 related articles for article (PubMed ID: 35625907)
21. SARS-CoV-2 RdRp Inhibitors Selected from a Cell-Based SARS-CoV-2 RdRp Activity Assay System.
Min JS; Kwon S; Jin YH
Biomedicines; 2021 Aug; 9(8):. PubMed ID: 34440200
[TBL] [Abstract][Full Text] [Related]
22. Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency.
Gordon CJ; Tchesnokov EP; Woolner E; Perry JK; Feng JY; Porter DP; Götte M
J Biol Chem; 2020 May; 295(20):6785-6797. PubMed ID: 32284326
[TBL] [Abstract][Full Text] [Related]
23. High Capability of Pentagalloylglucose (PGG) in Inhibiting Multiple Types of Membrane Ionic Currents.
Chang WT; Liu PY; Wu SN
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33316951
[TBL] [Abstract][Full Text] [Related]
24. Identification of Hypericin as a Candidate Repurposed Therapeutic Agent for COVID-19 and Its Potential Anti-SARS-CoV-2 Activity.
Matos ADR; Caetano BC; de Almeida Filho JL; Martins JSCC; de Oliveira MGP; Sousa TDC; Horta MAP; Siqueira MM; Fernandez JH
Front Microbiol; 2022; 13():828984. PubMed ID: 35222340
[TBL] [Abstract][Full Text] [Related]
25. Computational molecular docking and virtual screening revealed promising SARS-CoV-2 drugs.
Hosseini M; Chen W; Xiao D; Wang C
Precis Clin Med; 2021 Mar; 4(1):1-16. PubMed ID: 33842834
[TBL] [Abstract][Full Text] [Related]
26. Antiviral activity and possible mechanisms of action of pentagalloylglucose (PGG) against influenza A virus.
Liu G; Xiong S; Xiang YF; Guo CW; Ge F; Yang CR; Zhang YJ; Wang YF; Kitazato K
Arch Virol; 2011 Aug; 156(8):1359-69. PubMed ID: 21479599
[TBL] [Abstract][Full Text] [Related]
27. A drug repurposing screen identifies hepatitis C antivirals as inhibitors of the SARS-CoV2 main protease.
Baker JD; Uhrich RL; Kraemer GC; Love JE; Kraemer BC
PLoS One; 2021; 16(2):e0245962. PubMed ID: 33524017
[TBL] [Abstract][Full Text] [Related]
28. Broad Spectrum Antiviral Properties of Cardiotonic Steroids Used as Potential Therapeutics for Emerging Coronavirus Infections.
Jin YH; Jeon S; Lee J; Kim S; Jang MS; Park CM; Song JH; Kim HR; Kwon S
Pharmaceutics; 2021 Nov; 13(11):. PubMed ID: 34834252
[TBL] [Abstract][Full Text] [Related]
29. Repurposing of FDA-approved drugs as potential inhibitors of the SARS-CoV-2 main protease: Molecular insights into improved therapeutic discovery.
Ray AK; Sen Gupta PS; Panda SK; Biswal S; Bhattacharya U; Rana MK
Comput Biol Med; 2022 Mar; 142():105183. PubMed ID: 34986429
[TBL] [Abstract][Full Text] [Related]
30. In Silico Identification of a Potent Arsenic Based Approved Drug Darinaparsin against SARS-CoV-2: Inhibitor of RNA Dependent RNA polymerase (RdRp) and Essential Proteases.
Chowdhury T; Roymahapatra G; Mandal SM
Infect Disord Drug Targets; 2021; 21(4):608-618. PubMed ID: 32718300
[TBL] [Abstract][Full Text] [Related]
31. Quinoline and Quinazoline Derivatives Inhibit Viral RNA Synthesis by SARS-CoV-2 RdRp.
Zhao J; Zhang Y; Wang M; Liu Q; Lei X; Wu M; Guo S; Yi D; Li Q; Ma L; Liu Z; Guo F; Wang J; Li X; Wang Y; Cen S
ACS Infect Dis; 2021 Jun; 7(6):1535-1544. PubMed ID: 34038639
[TBL] [Abstract][Full Text] [Related]
32. RETRACTED ARTICLE: Discovery of (
Rabie AM
Chem Zvesti; 2021; 75(9):4669-4685. PubMed ID: 34025012
[TBL] [Abstract][Full Text] [Related]
33. Efficacious Preclinical Repurposing of the Nucleoside Analogue Didanosine against COVID-19 Polymerase and Exonuclease.
Rabie AM
ACS Omega; 2022 Jun; 7(25):21385-21396. PubMed ID: 35785294
[TBL] [Abstract][Full Text] [Related]
34. Targeting the Dimerization of the Main Protease of Coronaviruses: A Potential Broad-Spectrum Therapeutic Strategy.
Goyal B; Goyal D
ACS Comb Sci; 2020 Jun; 22(6):297-305. PubMed ID: 32402186
[TBL] [Abstract][Full Text] [Related]
35. [Optimization of expression conditions and determination the proteolytic activity of codon-optimized SARS-CoV-2 main protease in Escherichia coli].
Chen Y; Fu Z; Yan G; Lin Y; Liu X
Sheng Wu Gong Cheng Xue Bao; 2021 Apr; 37(4):1334-1345. PubMed ID: 33973446
[TBL] [Abstract][Full Text] [Related]
36. [Discovery of SARS-CoV-2 main protease inhibitors using an optimized FRET-based high-throughput screening assay].
Yan G; Li D; Qi H; Fu Z; Liu X; Zhang J; Chen Y
Sheng Wu Gong Cheng Xue Bao; 2022 Jun; 38(6):2236-2249. PubMed ID: 35786475
[TBL] [Abstract][Full Text] [Related]
37. Promising Experimental Anti-SARS-CoV-2 Agent "SLL-0197800": The Prospective Universal Inhibitory Properties against the Coming Versions of the Coronavirus.
Rabie AM; Abdel-Dayem MA; Abdalla M
ACS Omega; 2023 Oct; 8(39):35538-35554. PubMed ID: 37810715
[TBL] [Abstract][Full Text] [Related]
38. [Development of antiviral drugs based on inhibitors of the SARS-COV-2 main protease].
Sulimov AV; Shikhaliev KS; Pyankov OV; Shcherbakov DN; Chirkova VY; Ilin IS; Kutov DC; Tashchilova AS; Krysin MY; Krylskiy DV; Stolpovskaya NV; Volosnikova EA; Belenkaya SV; Sulimov VB
Biomed Khim; 2021 May; 67(3):259-267. PubMed ID: 34142533
[TBL] [Abstract][Full Text] [Related]
39. SARS-CoV-2 RNA dependent RNA polymerase (RdRp) targeting: an
Elfiky AA
J Biomol Struct Dyn; 2021 Jun; 39(9):3204-3212. PubMed ID: 32338164
[TBL] [Abstract][Full Text] [Related]
40. Identifying SARS-CoV-2 antiviral compounds by screening for small molecule inhibitors of nsp12/7/8 RNA-dependent RNA polymerase.
Bertolin AP; Weissmann F; Zeng J; Posse V; Milligan JC; Canal B; Ulferts R; Wu M; Drury LS; Howell M; Beale R; Diffley JFX
Biochem J; 2021 Jul; 478(13):2425-2443. PubMed ID: 34198323
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
